Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06616844 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers

Study acronym: IDEAL
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 2 months later Feb 2026 → May 2027
See other at-risk trials from ConvaTec Inc.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Feb 2026 to May 2027
    • Enrollment increased: 194 → 235 participants
    • Trial sites expanded: 9 → 21 locations
    • Study completion pushed from Jul 2026 to Jan 2028
    v5
  2. Study sites: 6 to 9v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 2024 to Feb 12, 2025
    • Study sites: 4 to 6
    v3
  4. Study title expanded, about 20 wordsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
ConvaTec Inc.
11 trials monitored
See 1 trial at risk
A multi-center, prospective, observer-blinded, randomized controlled clinical trial to evaluate the efficacy of PPECM augmented standard of care versus standard of care alone in the management of hard-to-heal diabetic foot ulcers.
Trial Details
NCT Number NCT06616844
Lead Sponsor ConvaTec Inc.
Conditions
(from sponsor)		 Wound Heal, Ulcer
Related terms Ulcer
Enrollment 235 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov